Latest Buy Backs News

Schaffer Corporation reported a modest 8.6% decline in net profit for FY26 to $22.2 million, with a rebound in Automotive Leather offset by a loss at Delta and strong gains from its South Connect Jandakot property development.

Challenger Limited has announced a fully franked dividend totaling AUD 0.175 per share for the six months ending 30 June 2026, including an ordinary dividend of AUD 0.16 and a special dividend of AUD 0.015. Shareholders can opt into a Dividend Reinvestment Plan with no discount, using a VWAP-based price.

Whitehaven Coal reported a 29% drop in underlying net profit to $227 million for FY26, despite record safety outcomes and successful debt refinancing that lowered funding costs and extended maturities.

Temple & Webster defied a tough consumer backdrop to post record FY26 revenue of A$665 million and is targeting a substantial 50-80% EBITDA increase in FY27 under new CEO Susie Sugden.

Mirvac Group delivered a robust FY26 with a 7% rise in operating profit to $508 million, a staggering 896% jump in statutory profit to $677 million, and announced a $200 million on-market buy-back, signalling confidence in its growth trajectory.

Carlton Investments lifted its profit by 6.1% to $41.18 million for FY2026, boosted by higher dividends, even as its equity portfolio value fell 6.2%. The company declared a final dividend increase including a special payout amid ongoing market volatility.

Regal Partners Global Investments (ASX:RG1) reversed last year's losses with a $141.6 million net profit, driven by strong returns in semiconductors, gold, and European banks. The company declared a fully franked final dividend of 5.0 cents per share and continued its on-market share buy-back program.

Whitefield Industrials (ASX:WHF) has transitioned to quarterly dividend payments, declaring fully franked dividends for June 2026 that imply a 6.4% annual yield on its recent share price.

Cogstate Ltd (ASX:CGS) posted a 15.9% rise in profit before tax to US$16.1 million for FY26, driven by a 116% surge in clinical trial sales contracts to $89 million and a 15% revenue increase. The company doubled its final dividend to A$0.04 per share, supported by a strong $118.5 million contracted revenue backlog.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.

Challenger Limited delivered a solid FY26 with normalised net profit after tax rising 3% to $468 million, supported by record annuity sales and strategic partnerships. The company also declared a 7% higher fully franked dividend and announced an upsized $450 million share buy-back.

Region Group (ASX: RGN) delivered solid FY26 results with a 3.2% increase in Funds From Operations per security, a 9.8% total security holder return, and a leadership change as Greg Chubb took the helm as CEO.